PERSPECTA

News from every angle

← Back to headlines

Wolfe Research Upgrades Merck Stock Target Following Positive Cancer Drug Trial Results

Investment analysts have raised their price targets for Merck shares after clinical data demonstrated promising efficacy for the company's oncology pipeline, boosting investor confidence.

PostShare

Sources

Showing 0 of 2 sources

No articles available in your preferred languages.

2 articles available in other languages below.

Yahooilo2h ago

Merck (MRK) Surges on a Melanoma Win. Can Intismeran Extend Keytruda’s Growth Runway?

Read full article →
investing-comFrench6h ago

Wolfe Research raises Merck stock price target on cancer drug data

Read full article →

Coverage Timeline

First report: investing-com · 25 Aug, 10:24Full coverage: 2 · 4hWindow: 4h
Left-leaningCenterRight-leaning
investing-com25 Aug, 10:24First to report

Wolfe Research raises Merck stock price target on cancer drug data

4h later
Yahoo25 Aug, 14:21Latest update

Merck (MRK) Surges on a Melanoma Win. Can Intismeran Extend Keytruda’s Growth Runway?

Related Stories

Canada Imposes Retaliatory Tariffs on US Goods Amid Trade Dispute

13m ago

SelectQuote Shares Decline on Q4 Revenue Miss and Weak Outlook

31m ago

Gatik Raises $200 Million Amid Growing Autonomous Freight Demand

38m ago

Leonardo Maria Del Vecchio Resigns from EssilorLuxottica Amid Family Dispute

39m ago